A month’s supply of Wegovy costs roughly $1,350 at list price. A month’s supply of Zepbound runs about $1,060. Even with insurance negotiations and manufacturer coupons, many patients still pay $500 to $700 out of pocket. For the more than 60 million Americans enrolled in Medicare, the price has been even steeper in practical terms: the program simply refused to cover these drugs for weight loss, no matter what a patient could afford to pay.
That changes on July 1, 2026. Under a new Medicare GLP-1 Bridge demonstration announced by the Centers for Medicare and Medicaid Services, eligible beneficiaries with Part D coverage will be able to fill prescriptions for Wegovy, Zepbound, and a newer oral semaglutide called Foundayo at a flat $50 monthly copay. The program runs through December 31, 2027, and it marks the first time Medicare has offered broad coverage for GLP-1 medications specifically for weight reduction, not just for diabetes or heart disease.
For millions of older Americans who have watched these drugs reshape obesity treatment from the sidelines, blocked by a decades-old statutory prohibition, the Bridge is not a modest policy tweak. It is the difference between having access to treatment and not having it at all.
Why Medicare has never covered weight-loss drugs before
The exclusion traces back to Section 1927(d)(2) of the Social Security Act, which bars Medicare Part D from covering drugs prescribed for weight loss, weight gain, or anorexia. When Congress created the Part D prescription drug benefit in 2003, that prohibition carried over. For years, it barely mattered. Few effective weight-loss medications existed, and the ones available carried serious safety concerns that limited their use.
GLP-1 receptor agonists upended that reality. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) demonstrated sustained weight reductions of 15% to 20% or more in large clinical trials, along with measurable cardiovascular benefits. Private insurers and employer health plans began covering them. Medicare, locked in by statute, largely could not.
A partial workaround appeared in March 2024, when the FDA approved Wegovy for a cardiovascular risk-reduction indication in adults with established heart disease and obesity or overweight. That approval allowed some Wegovy prescriptions to qualify for Part D coverage when prescribed to lower the risk of heart attack and stroke, since the drug was no longer being used solely for weight loss. But the cardiovascular indication is narrow. It does not reach the much larger population of Medicare beneficiaries who are obese but have not yet been diagnosed with cardiovascular disease.
The Bridge demonstration takes a different path. Using CMS’s authority to run time-limited payment models, it explicitly covers GLP-1 medications for weight reduction and weight maintenance. It is a workaround rather than a permanent legislative fix, but it opens the door far wider than the cardiovascular indication ever could.
Which drugs are covered and which are not
The Bridge program page published by CMS lists the specific products and National Drug Codes eligible for the $50 copay. The covered medications include:
- Wegovy (semaglutide), in all injectable formulations plus tablet versions
- Zepbound (tirzepatide), but only in the KwikPen delivery format
- Foundayo, a newer oral semaglutide product approved for weight management
Those boundaries matter. Other GLP-1 medications, including Ozempic and Mounjaro, contain the same active ingredients but are approved only for type 2 diabetes and are not part of the Bridge demonstration. Alternative delivery formats of Zepbound beyond the KwikPen are also excluded. Beneficiaries using those products would continue under standard Part D rules, where coverage and copays vary by plan.
Notably, compounded versions of semaglutide and tirzepatide, which millions of Americans have turned to as a lower-cost alternative through compounding pharmacies, are not included in the Bridge. The FDA has been tightening enforcement against compounded GLP-1 products as brand-name supply has stabilized, and the Bridge demonstration covers only FDA-approved branded formulations.
What beneficiaries need to know right now
CMS has confirmed the $50 monthly copay and the July 1 start date, but several practical details remain incomplete as of June 2026. The agency has not yet published full clinical eligibility criteria. It is unclear whether beneficiaries will need to meet a specific body mass index threshold, demonstrate obesity-related comorbidities, or obtain prior authorization before filling a prescription.
For beneficiaries who want to prepare, the most useful step right now is a conversation with a primary care physician or endocrinologist about whether a GLP-1 medication is clinically appropriate. Physicians can review the covered drug list and NDCs on the CMS website to determine which products qualify. Beneficiaries should also call their Part D plan directly to ask how the demonstration will be implemented, since plans may vary in how quickly they update formularies and claims processing.
One question that will come up frequently: what about people already taking GLP-1 drugs for diabetes? Many Medicare beneficiaries use Ozempic or Mounjaro for blood sugar control under Part D, often at copays well above $50. CMS has not clarified whether those individuals can shift some or all of their therapy to the Bridge if they also meet weight-related criteria, or whether the diabetes and weight-loss treatment pathways will remain separate. For patients managing both conditions, that distinction could affect both cost and continuity of care.
The supply question
GLP-1 medications have been dogged by intermittent shortages since demand surged in 2023 and 2024. The FDA maintained tirzepatide on its drug shortage list for much of that period, and semaglutide supply tightened as well. Both Novo Nordisk and Eli Lilly have invested billions in manufacturing expansion, and supply conditions have improved heading into mid-2026.
But opening a new coverage pathway for millions of Medicare beneficiaries could test that capacity again. CMS has not publicly addressed how the Bridge demonstration will interact with supply constraints. If demand spikes and pharmacies face allocation limits, the $50 copay becomes less meaningful for patients who cannot actually fill their prescriptions. Neither Novo Nordisk nor Eli Lilly has released production forecasts tied specifically to the Medicare demonstration, though both companies have signaled confidence in their ability to meet growing demand.
Who pays the difference between $50 and the actual cost
How CMS arrived at a $50 monthly copay, and who absorbs the gap between that figure and the drug’s wholesale cost, is not fully transparent. According to published list prices from Novo Nordisk and Eli Lilly, Wegovy carries a list price of roughly $1,350 per month and Zepbound approximately $1,060. Even after manufacturer rebates and pharmacy benefit manager negotiations, the distance between $50 and the net cost to the federal government is substantial.
CMS has not disclosed the rebate agreements, supplemental discounts, or federal spending projections behind the demonstration. That lack of transparency makes it difficult for independent analysts to assess whether the Bridge is designed to be roughly budget-neutral, modestly subsidized, or a significant new federal expenditure. The answer will shape whether the model can scale into a permanent Part D benefit or whether costs force policymakers to narrow access after 2027.
The broader fiscal pressure is real. Multiple Congressional Budget Office analyses of proposals to repeal the Part D weight-loss drug exclusion, including scores related to the Treat and Reduce Obesity Act, have projected costs in the tens of billions of dollars over a decade, depending on uptake assumptions. The Bridge demonstration, capped at 18 months, limits near-term exposure. But if the program proves popular, the political and budgetary dynamics of letting it expire will be fierce.
What comes after the Bridge expires
CMS has described the Bridge as a precursor to a longer-term initiative called BALANCE (Broadening Affordability and Leveraging Alternative Negotiations for Coverage and Equity). According to a CMS innovation insight document, BALANCE is intended to build a more durable framework for GLP-1 affordability, potentially incorporating value-based arrangements tied to clinical outcomes like sustained weight loss or reduced cardiovascular events.
As of June 2026, BALANCE remains in the request-for-applications stage. CMS has not committed to a launch date or a detailed design. That means the Bridge is, for now, a standalone experiment. If it generates strong utilization data and measurable health improvements, it could build the case for permanent legislative change. If costs run high or access concentrates among wealthier, healthier beneficiaries rather than the populations with the greatest clinical need, the argument for expansion weakens considerably.
The demonstration was launched under the Trump administration, which framed it as a way to lower drug costs for seniors. Whether the Bridge and its successor BALANCE survive past 2027 may depend heavily on the political environment at that time, including which administration holds power and whether Congress acts to make GLP-1 coverage a permanent part of Medicare.
Congress could also act on its own. Several bills introduced in recent sessions have proposed repealing or narrowing the Part D weight-loss drug exclusion. None have reached a floor vote. But the Bridge creates a new political reality: once millions of Medicare beneficiaries are paying $50 a month for medications that visibly improve their health, taking that benefit away becomes a much harder vote to cast.
How to prepare before July 1
The Bridge demonstration is not a permanent entitlement. It is a structured test with a fixed start date, a fixed end date, and a list of covered products that could change. But for Medicare beneficiaries who have spent years unable to afford GLP-1 medications, or who never explored them because their insurance would not cover the cost, July 1 represents something genuinely new.
The practical steps are clear: check the covered drug list on the CMS website, talk to your doctor about whether a GLP-1 medication makes sense for you, and contact your Part D plan to ask how it will handle Bridge prescriptions. The larger policy questions, about long-term cost, supply, eligibility rules, and what happens when the demonstration ends in 2028, remain unresolved.
But for the first time, Medicare is treating obesity with the same pharmacological tools that the rest of the insurance market adopted years ago. Whether that access survives beyond December 2027 depends entirely on what the next 18 months reveal.
